• Je něco špatně v tomto záznamu ?

Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents

M. Krecmerová, A. Holý, G. Andrei, K. Pomeisl, T. Tichý, P. Brehová, M. Masojídková, M. Dracínský, R. Pohl, G. Laflamme, L. Naesens, H. Hui, T. Cihlar, J. Neyts, E. De Clercq, J. Balzarini, R. Snoeck,

. 2010 ; 53 (19) : 6825-37.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12026131

9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) and its cyclic form were selected for further evaluation as potential drug candidates against poxvirus infections. To increase bioavailability of these compounds, synthesis of their structurally diverse ester prodrugs was carried out: alkoxyalkyl (hexadecyloxypropyl, octadecyloxyethyl, hexadecyloxyethyl), pivaloyloxymethyl (POM), 2,2,2-trifluoroethyl, butylsalicylyl, and prodrugs based on peptidomimetics. Most HPMPDAP prodrugs were synthesized in the form of monoesters as well as the corresponding cyclic phosphonate esters. The activity was evaluated not only against vaccinia virus but also against different herpes viruses. The most potent and active prodrugs against vaccinia virus were the alkoxyalkyl ester derivatives of HPMPDAP, with 50% effective concentrations 400-600-fold lower than those of the parent compound. Prodrugs based on peptidomimetics, the 2,2,2-trifluoroethyl, the POM, and the butylsalicylyl derivatives, were able to inhibit vaccinia virus replication at 50% effective concentrations that were equivalent or ∼10-fold lower than those observed for the parent compounds.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12026131
003      
CZ-PrNML
005      
20140625094814.0
007      
ta
008      
120817s2010 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1021/jm901828c $2 doi
035    __
$a (PubMed)20809641
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Krecmerová, Marcela $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic. marcela@uochb.cas.cz
245    10
$a Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents / $c M. Krecmerová, A. Holý, G. Andrei, K. Pomeisl, T. Tichý, P. Brehová, M. Masojídková, M. Dracínský, R. Pohl, G. Laflamme, L. Naesens, H. Hui, T. Cihlar, J. Neyts, E. De Clercq, J. Balzarini, R. Snoeck,
520    9_
$a 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) and its cyclic form were selected for further evaluation as potential drug candidates against poxvirus infections. To increase bioavailability of these compounds, synthesis of their structurally diverse ester prodrugs was carried out: alkoxyalkyl (hexadecyloxypropyl, octadecyloxyethyl, hexadecyloxyethyl), pivaloyloxymethyl (POM), 2,2,2-trifluoroethyl, butylsalicylyl, and prodrugs based on peptidomimetics. Most HPMPDAP prodrugs were synthesized in the form of monoesters as well as the corresponding cyclic phosphonate esters. The activity was evaluated not only against vaccinia virus but also against different herpes viruses. The most potent and active prodrugs against vaccinia virus were the alkoxyalkyl ester derivatives of HPMPDAP, with 50% effective concentrations 400-600-fold lower than those of the parent compound. Prodrugs based on peptidomimetics, the 2,2,2-trifluoroethyl, the POM, and the butylsalicylyl derivatives, were able to inhibit vaccinia virus replication at 50% effective concentrations that were equivalent or ∼10-fold lower than those observed for the parent compounds.
650    _2
$a adenin $x analogy a deriváty $x chemická syntéza $x chemie $x farmakologie $7 D000225
650    _2
$a antivirové látky $x chemická syntéza $x chemie $x farmakologie $7 D000998
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a kultivované buňky $7 D002478
650    _2
$a estery $7 D004952
650    _2
$a Herpesviridae $x účinky léků $7 D006564
650    _2
$a lidé $7 D006801
650    _2
$a organofosforové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D009943
650    _2
$a Poxviridae $x účinky léků $7 D011212
650    _2
$a prekurzory léčiv $x chemická syntéza $x chemie $x farmakologie $7 D011355
650    _2
$a RNA-viry $x účinky léků $7 D012328
650    _2
$a stereoizomerie $7 D013237
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a virologie $x metody $7 D014773
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Holý, Antonín, $d 1936-2012 $7 jn20000401004
700    1_
$a Andrei, Graciela $7 gn_A_00006456
700    1_
$a Pomeisl, Karel
700    1_
$a Tichý, Tomás
700    1_
$a Brehová, Petra
700    1_
$a Masojídková, Milena
700    1_
$a Dracínský, Martin
700    1_
$a Pohl, Radek
700    1_
$a Laflamme, Genevieve
700    1_
$a Naesens, Lieve
700    1_
$a Hui, Hon
700    1_
$a Cihlar, Tomas
700    1_
$a Neyts, Johan
700    1_
$a De Clercq, Erik
700    1_
$a Balzarini, Jan
700    1_
$a Snoeck, Robert
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 53, č. 19 (2010), s. 6825-37
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20809641 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20140625095046 $b ABA008
999    __
$a ok $b bmc $g 948173 $s 783477
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 53 $c 19 $d 6825-37 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20120817/10/04

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...